Corcept Therapeutics (NASDAQ:CORT) Trading Up 10.3% Following Analyst Upgrade

Corcept Therapeutics Incorporated (NASDAQ:CORT) shares rose 10.3% during mid-day trading on Wednesday after Canaccord Genuity Group raised their price target on the stock from $100.00 to $110.00. Canaccord Genuity Group currently has a buy rating on the stock. Corcept Therapeutics traded as high as $34.50 and last traded at $37.2980. Approximately 81,249 shares were traded during trading, a decline of 96% from the average daily volume of 1,995,047 shares. The stock had previously closed at $33.82.

Other equities analysts have also recently issued reports about the stock. UBS Group assumed coverage on shares of Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price for the company. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Truist Financial upgraded Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday. Finally, Wolfe Research raised Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Corcept Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $77.67.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total value of $817,400.00. Following the sale, the insider owned 1,235 shares in the company, valued at $50,474.45. This trade represents a 94.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director G Leonard Baker, Jr. purchased 100,000 shares of the stock in a transaction dated Tuesday, March 17th. The shares were bought at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the acquisition, the director directly owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This represents a 9.55% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders sold 60,000 shares of company stock valued at $2,241,035. 20.80% of the stock is owned by insiders.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer — the primary catalyst behind the rally; approval completed ahead of schedule and trial data showed a survival benefit. BusinessWire: FDA Approves Lifyorli
• Positive Sentiment: Brokerage support and higher targets: multiple firms have upgraded or reiterated buy/strong‑buy ratings and at least one firm raised its price target, which supports upside expectations after the approval. Benzinga: Canaccord price‑target update
• Positive Sentiment: Sizable insider buying (a director bought 100,000 shares in mid‑March) cited by commentators as a confidence signal that likely helped fuel bullish positioning ahead of the approval. QuiverQuant: Insider buy & catalyst analysis
• Neutral Sentiment: Market structure and volatility: the stock saw trading halts and large intraday prints as the market re‑priced the company on the approval; expect continued high volume and volatility. Reuters: Market reaction coverage
• Negative Sentiment: Multiple securities‑class‑action alerts filed/announced (Hagens Berman, Kaplan Fox, Rosen, Pomerantz, others) alleging disclosure issues tied to prior regulatory and patent matters — material legal risk that could lead to expenses, distractions or settlement pressure. GlobeNewswire: Hagens Berman alert
• Negative Sentiment: Recent insider selling by senior executives (disclosed March filings) reduces insider ownership and may concern some investors even as other insiders bought shares. SEC filing: insider sale
• Negative Sentiment: Some analyst commentary (and at least one note flagged by coverage) suggests more cautious near‑term forecasts despite the approval — watch for updated guidance, launch assumptions and uptake projections. AmericanBankingNews: analyst note

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CORT. Pathstone Holdings LLC raised its holdings in Corcept Therapeutics by 0.8% during the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock worth $1,497,000 after buying an additional 144 shares during the last quarter. Campbell Newman Asset Management Inc. increased its position in shares of Corcept Therapeutics by 0.5% during the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after acquiring an additional 170 shares in the last quarter. Clearstead Advisors LLC raised its holdings in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares during the last quarter. Gould Capital LLC lifted its position in Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares in the last quarter. Finally, Advisors Asset Management Inc. boosted its stake in Corcept Therapeutics by 1.3% during the 2nd quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company’s stock valued at $1,390,000 after purchasing an additional 237 shares during the last quarter. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The business has a 50 day simple moving average of $37.47 and a 200-day simple moving average of $61.00. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of 46.99 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 EPS. Equities research analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.